In the future, it could be tried to improve the local control rate and prolong the survival of glioblastoma patients who undergo surgical treatment with standard post-surgical adjuvant concurrent radiotherapy (total dose of 60Gy for more than 6 weeks with daily temozolomide, followed by 6 cycles of temozolomide maintenance therapy) with activation of piezo1 by the DC-BP vaccine, offering new possibilities for glioblastoma treatment (Yu et al., 2024). Here, PIEZO1 is linked to glioblastoma.